PPARAgonists in Adaptive Immunity: What Do Immune Disorders and Their Models Have to Tell Us?
Open Access
- 1 January 2013
- journal article
- review article
- Published by Wiley in PPAR Research
- Vol. 2013, 1-9
Abstract
Adaptive immunity has evolved as a very powerful and highly specialized tool of host defense. Its classical protagonists are lymphocytes of the T- and B-cell lineage. Cytokines and chemokines play a key role as effector mechanisms of the adaptive immunity. Some autoimmune and inflammatory diseases are caused by disturbance of the adaptive immune system. Recent advances in understanding the pathogenesis of autoimmune diseases have led to research on new molecular and therapeutic targets. PPARγare members of the nuclear receptor superfamily and are transcription factors involved in lipid metabolism as well as innate and adaptive immunity. PPARγis activated by synthetic and endogenous ligands. Previous studies have shown that PPAR agonists regulate T-cell survival, activation and T helper cell differentiation into effector subsets: Th1, Th2, Th17, and Tregs. PPARγhas also been associated with B cells. The present review addresses these issues by placing PPARγagonists in the context of adaptive immune responses and the relation of the activation of these receptors with the expression of cytokines involved in adaptive immunity.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco
- Financiadora de Estudos e Projetos
This publication has 96 references indexed in Scilit:
- PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cellsNature, 2012
- Targeting Orphan Nuclear Receptors for Treatment of Metabolic Diseases and AutoimmunityChemistry & Biology, 2012
- The Role of Cytokines in the Pathogenesis and Treatment of Systemic Lupus ErythematosusJournal of Interferon & Cytokine Research, 2011
- The Dysregulation of Cytokine Networks in Systemic Lupus ErythematosusJournal of Interferon & Cytokine Research, 2011
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisNew England Journal of Medicine, 2010
- The nuclear receptor PPARγ selectively inhibits Th17 differentiation in a T cell–intrinsic fashion and suppresses CNS autoimmunityJournal of Experimental Medicine, 2009
- Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parametersNature Medicine, 2009
- Expression of peroxisome proliferator-activated receptor-γ in macrophage suppresses experimentally induced colitisAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2007
- IL-23 is essential for T cell–mediated colitis and promotes inflammation via IL-17 and IL-6Journal of Clinical Investigation, 2006
- Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNature, 2003